CCM
INKT icon

Chilton Capital Management’s MiNK Therapeutics INKT Stock Holding History

Chilton Capital Management’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31
Closed -$232 – 622
2024
Q3 		$232 Hold
31
– – ﹤0.01% 632
2024
Q2 		$294 Hold
31
– – ﹤0.01% 593
2024
Q1 		$281 Hold
31
– – ﹤0.01% 590
2023
Q4 		$331 Hold
31
– – ﹤0.01% 591
2023
Q3 		$340 Hold
31
– – ﹤0.01% 497
2023
Q2 		$649 Buy
+31
New +$621 ﹤0.01% 523

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Chilton Capital Management's INKT Position: Q4 2024 in Review

Chilton Capital Management sold out of MiNK Therapeutics (INKT) in Q4 2024, closing a stake of 31 shares — an estimated $232 sold.

Chilton Capital Management first reported a position in INKT in Q2 2023 and held it in 6 quarters. The position peaked at $649 in Q2 2023. 21 funds tracked by Wall St. Rank hold INKT as of Q4 2024.

  • Chilton Capital Management reported no remaining MiNK Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Chilton Capital Management sold 31 MiNK Therapeutics shares in Q4 2024, an estimated $232.
  • Chilton Capital Management first reported a position in MiNK Therapeutics in Q2 2023 and held it in 6 quarters.
  • Chilton Capital Management's MiNK Therapeutics position peaked at $649 in Q2 2023.
  • 21 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q4 2024.

Based on Chilton Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.